Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 250
Single User License Price INR 17500
Corporate User License Price USD 750
Corporate User License Price INR 52500
Site License Price USD 500
Site License Price INR 35000
Request a Quote

Report Title

Ultragenyx Pharmaceutical Inc (RARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Quote Request for License Type
License Type Price  
Single User License USD 250
Site License USD 500
Enterprise Wide License USD 750
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Ultragenyx Pharmaceutical Inc (RARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


Quote Request for License Type
License Type Price  
Single User License USD 250
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Ultragenyx Pharmaceutical Inc (RARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Ultragenyx Pharmaceutical Inc (RARE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile



Executive Summary

Summary

Ultragenyx Pharmaceutical Inc (Ultragenyx) is a biotechnology company that develops life-enhancing therapeutics for rare and ultra-rare genetic diseases. Its only marketed product, Mepsevii (vestronidase alfa) is the first indication approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome). The company's pipeline comprises Burosumab (KRN23 or UX023), a fully human monoclonal antibody in Phase 3 for the treatment of X-linked hypophosphatemia (XLH); and Burosumab in Phase 2 for the treatment of tumor-induced osteomalacia (TIO); UX007 in Phase 3 for patients with Glut1 DS; UX007 as an oral administration in Phase 2 for the treatment of LC-FAOD. DTX301, in Phase 2 for the treatment of ornithine transcarbamylase (OTC) deficiency; DTX401 in Phase 1 for the treatment of GSDIa, and DTX201 in Phase 1 for the treatment of hemophilia A. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc (RARE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ultragenyx Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 11

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 15

Venture Financing 15

Dimension Therapeutics Raises USD65 Million in Series B Financing 15

Dimension Therapeutics Raises USD30 Million in Venture Financing 17

Dimension Therapeutics Raises USD5 Million in Series A Financing 18

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 19

Ultragenyx Pharma Raises USD 15.1 Million In Venture Financing 21

Partnerships 22

Aptuit Enters into Agreement with Dimension Therapeutics 22

Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 23

Ultragenyx Pharma Enters into Research Agreement with Saint Louis University 24

Dimension Therapeutics Enters into R&D Agreement with Eunice Kennedy Shriver National Institute 25

Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 26

Licensing Agreements 27

Ultragenyx Pharma Exercises Option for Licensing Agreement with Regenxbio 27

Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 28

Ultragenyx Pharma Enters into Licensing Agreement with Arcturus Therapeutics 29

ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 30

Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 31

Bayer HealthCare Enters into Licensing Agreement with Dimension Therapeutics for Hemophilia A 33

ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 34

Ultragenyx Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For KRN23 35

Ultragenyx Pharma Expands Licensing Agreement With Baylor Research Institute For Triheptanoin 37

Ultragenyx Pharmaceutical Amends its Licensing Agreement with St. Jude Children's Research Hospital 39

Ultragenyx Pharma Enters into Licensing Agreement with HIBM Research 40

Ultragenyx Pharma Enters into Licensing Agreement with UniQuest for Triheptanoin 41

Ultragenyx Pharma Enters Into Licensing Agreement With Saint Louis University 42

Equity Offering 43

Ultragenyx Pharma Plans to Raise up to USD72.6 Million in Public Offering of Shares 43

Ultragenyx Pharma Raises USD287.5 Million in Public Offering of Shares 44

Ultragenyx Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 46

Dimension Therapeutics Plans to Raise up to USD35 Million in Public Offering of Shares 47

Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 48

Dimension Therapeutics Prices IPO for USD72.86 Million 50

Ultragenyx Pharma Completes Public Offering of Shares for USD303.6 Million 52

Ultragenyx Pharma Raises USD162 Million in Public Offering of Shares 54

Ultragenyx Pharma Raises USD76.7 Million in Public Offering of Shares 56

Ultragenyx Pharma Completes IPO For USD 139 Million 58

Asset Transactions 59

Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 59

Acquisition 60

Ultragenyx Pharma Acquires Dimension Therapeutics for USD152.3 Million 60

RegenxBio to Acquire Dimension Therapeutics 62

Ultragenyx Pharmaceutical Inc-Key Competitors 64

Ultragenyx Pharmaceutical Inc-Key Employees 65

Ultragenyx Pharmaceutical Inc-Locations And Subsidiaries 66

Head Office 66

Other Locations & Subsidiaries 66

Recent Developments 67

Financial Announcements 67

Nov 05, 2018: Ultragenyx reports third quarter 2018 financial results and corporate update 67

Aug 02, 2018: Ultragenyx reports second quarter 2018 financial results and corporate update 69

May 07, 2018: Ultragenyx Reports First Quarter 2018 Financial Results 71

Feb 20, 2018: Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Corporate Update 73

Nov 02, 2017: Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update 76

Jul 27, 2017: Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update 78

May 04, 2017: Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update 80

Feb 16, 2017: Ultragenyx Reports Fourth Quarter and Full Year 2016 Financial Results and Corporate Update 82

Corporate Communications 84

Sep 17, 2018: Ultragenyx Pharmaceutical appoints Dr Wladimir Hogenhuis as chief operating officer 84

Jan 29, 2018: Ultragenyx Names Camille L. Bedrosian as Chief Medical Officer and Executive Vice President 85

Apr 10, 2017: Ultragenyx Appoints Deborah Dunsire, M.D., to Board of Directors 86

Legal and Regulatory 87

Aug 02, 2018: Certara Software or Services supported 95% of the US FDA novel drug approvals in first half of 2018 87

Product News 88

11/16/2017: Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 88

08/31/2017: Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase Deficiency 89

07/30/2018: Ultragenyx doses first patient in DTX401 Phase 1/2 study to treat GSDIa 90

04/24/2017: Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting 91

04/23/2018: Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia 93

03/09/2017: Dimension Therapeutics Provides Update on DTX-101 94

03/07/2018: Ultragenyx Announces Positive Topline Results and DMC Review from First Cohort of Phase 1/2 Clinical Study of DTX301, an Investigational Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 96

01/31/2017: Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension's Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B 98

01/07/2018: Ultragenyx Announces Positive Interim Topline Results From First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency 100

Product Approvals 101

Aug 29, 2018: Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders 101

Clinical Trials 102

Jan 04, 2018: Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty Acid Oxidation Disorder Patients 102

Apr 27, 2017: Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders 103

Mar 22, 2017: Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study 104

Appendix 106

Methodology 106

About GlobalData 106

Contact Us 106

Disclaimer 106

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Ultragenyx Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Ultragenyx Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Ultragenyx Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 11

Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Dimension Therapeutics Raises USD65 Million in Series B Financing 15

Dimension Therapeutics Raises USD30 Million in Venture Financing 17

Dimension Therapeutics Raises USD5 Million in Series A Financing 18

Ultragenyx Pharma Raises USD 75 Million In Series B Financing 19

Ultragenyx Pharma Raises USD 15.1 Million In Venture Financing 21

Aptuit Enters into Agreement with Dimension Therapeutics 22

Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 23

Ultragenyx Pharma Enters into Research Agreement with Saint Louis University 24

Dimension Therapeutics Enters into R&D Agreement with Eunice Kennedy Shriver National Institute 25

Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 26

Ultragenyx Pharma Exercises Option for Licensing Agreement with Regenxbio 27

Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 28

Ultragenyx Pharma Enters into Licensing Agreement with Arcturus Therapeutics 29

ReGenX Biosciences Enters into Option And Licensing Agreement with Dimension Therapeutics 30

Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 31

Bayer HealthCare Enters into Licensing Agreement with Dimension Therapeutics for Hemophilia A 33

ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 34

Ultragenyx Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For KRN23 35

Ultragenyx Pharma Expands Licensing Agreement With Baylor Research Institute For Triheptanoin 37

Ultragenyx Pharmaceutical Amends its Licensing Agreement with St. Jude Children's Research Hospital 39

Ultragenyx Pharma Enters into Licensing Agreement with HIBM Research 40

Ultragenyx Pharma Enters into Licensing Agreement with UniQuest for Triheptanoin 41

Ultragenyx Pharma Enters Into Licensing Agreement With Saint Louis University 42

Ultragenyx Pharma Plans to Raise up to USD72.6 Million in Public Offering of Shares 43

Ultragenyx Pharma Raises USD287.5 Million in Public Offering of Shares 44

Ultragenyx Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 46

Dimension Therapeutics Plans to Raise up to USD35 Million in Public Offering of Shares 47

Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 48

Dimension Therapeutics Prices IPO for USD72.86 Million 50

Ultragenyx Pharma Completes Public Offering of Shares for USD303.6 Million 52

Ultragenyx Pharma Raises USD162 Million in Public Offering of Shares 54

Ultragenyx Pharma Raises USD76.7 Million in Public Offering of Shares 56

Ultragenyx Pharma Completes IPO For USD 139 Million 58

Novartis Acquires Rare Pediatric Disease Priority Review Voucher from Ultragenyx Pharma for USD130 Million 59

Ultragenyx Pharma Acquires Dimension Therapeutics for USD152.3 Million 60

RegenxBio to Acquire Dimension Therapeutics 62

Ultragenyx Pharmaceutical Inc, Key Competitors 64

Ultragenyx Pharmaceutical Inc, Key Employees 65

Ultragenyx Pharmaceutical Inc, Subsidiaries 66

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Ultragenyx Pharmaceutical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person